Due diligence has been taken by the publishers,
editors, and authors of this book to assure the accuracy of the information
published and to describe generally accepted practices. The contributors herein
have carefully checked to ensure that the drug selections and dosages set forth
in this text arc accurate and in accord with the standards accepted at the time
of publication. Notwithstanding, as new research, changes in government
regulations, and knowledge from clinical experience relating to drug therapy
and drug reactions constantly occurs, the reader is advised to check the
product information provided by the manufacturer of each drug for any change in
dosages or for additional warnings and contraindications. This is of utmost
importance when the recommended drug herein is a new or infrequently used drug.
It is the responsibility of the treating physician to determine dosages and
treatment strategies for individual patients. Further it is the responsibility
of the health care provider to ascertain the Food and Drug Administration
status of each drug or device used in their clinical practice. The publisher,
editor's, and authors ate not responsible for errors or omissions or for any
consequences from tlie application of the iufor mation presented in this book
and make no warranty, express or implied, with respect to the contents in this
publication.
Кол-во страниц:470
Язык:Английский
Издательство:Humana Press Inc
Foreword by E. Donnall Thomas. v
Foreword by David J. Weatherall. vii
Preface. ix
Contributors. xv
Part I. Molecular Markers.
Selecting the Right Targets for Cancer Therapy. Miguel H. Bronchud and William P. Peters. 3
Clinical Importance of Prognostic Factors: Moving from Scientifically. Interesting to Clinically Useful Daniel F. Hayes. 29
Genetic Markers in Sporadic Tumors. S. Birindelli, A. Aiello, C. Lavarino, G. Sozzi, Silvana Pilotti, and Marco A. Pierotti. 45
Cellular and Tissue Markers in Solid Tumors. Thomas Lin da hi, Torbjon Notberg, Gunnar Astrom, Sigrid Sjogren, and C. Jonas Bergh. 95
Circulating Tumor Markers. Alan Horwich and Gill Ross. 111
Part II. Diseased Regulatory Pathways.
Growth Factor-Signaling Pathways in Cancer Daniel Kalderon. 127
Estrogen Action and Breast Cancer. Hong Liu and V. Craig Jordan. 169
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics Leonardo Brizuela, Jerio Gyuris, and Muzammil Mansuri. 197
Apoptosis Pathways: Clinical Relevance. Caroline Archer, Peter Trott, and Mitchell Dowsett. 237
DNA Repair Pathways: Mechanisms and Defects in the Maintenance of Genome Stability Murray O. Robinson. 257
Angiogenesis Switch Pathways. Jatime Piulats and Francesc Mitjans. 271
Invasion and Metastasis. Maria Rosa Bani and Rafaella Giavazzi. 297
Molecular Pathways of Drug Resistance. Christos Talis, Carlos G. Ferreira, Herbert M. Pineda, and. Giuseppe Giaccone. 323
Part III. Future Directions.
Antitumor Immunity as Therapy for Human Cancer. Angela A. Cardoso. 359
Emerging Technologies: Molecular Targets and the Drug Delivery Process. Matthew Moyle and Michael Palazzolo. 395
Emerging Molecular Therapies for Cancer. Karol Sikora. 411
Emerging Molecular Therapies: Small-Molecule Drugs. Paul Workman. 421
Glossary. 439
Index. 443